Company registration number 14496144 (England and Wales)
GONMISOL UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
GONMISOL UK LIMITED
CONTENTS
Page
Independent auditor's report
1 - 3
Balance sheet
4
Notes to the financial statements
5 - 13
GONMISOL UK LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GONMISOL UK LIMITED
- 1 -
Opinion

We have audited the financial statements of Gonmisol UK Limited (the 'company') for the year ended 31 December 2025 which comprise , the balance sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

 

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

GONMISOL UK LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GONMISOL UK LIMITED (CONTINUED)
- 2 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

 

• We obtained an understanding of the legal and regulatory frameworks that are applicable to the company and determined that the most significant are those that relate to the reporting framework (FRS102 and the Companies Act 2006) and the relevant tax compliance regulations;

 

• We understood how the company is complying with those frameworks by making enquiries of management and those responsible for legal and compliance procedures, including internal legal counsel. We corroborated these enquiries through our review of board meeting minutes as well as considering the results of our audit procedures and noted no contradictory evidence. We further understood the adoption of accounting standards and considered the compliance with the above laws;

 

• Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Our procedures involved review of board meeting minutes and enquiries of management around instances of fraud, non-compliance with laws and regulations and actual or potential litigation and claims, as well as review of legal expenses incurred during the year and the claims and the litigation register;

 

GONMISOL UK LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF GONMISOL UK LIMITED (CONTINUED)
- 3 -

• We assessed the susceptibility of the company’s financial statements to material misstatement, including how fraud might occur by performing enquiries with management and those charged with governance about their knowledge of actual and suspected fraud affecting the entity and performing tests of fraud and the related controls to help prevent, deter and detect fraud. We also considered performance targets and whether there are opportunities or incentives for management to manipulate the financial statements. As a result, we identified a fraud risk on revenue recognition due to management override, specifically improper revenue recognition; and

 

• We designed our audit procedures to respond to the identified fraud risk. We understood the controls that the Company has established to address the risk identified or that otherwise prevent, deter, and detect fraud; and how senior management monitors these controls. Our procedures involved understanding of revenue recognition process, testing material reversals post year end, and testing of topside manual credit adjustments to revenue, with a focus on higher‑risk or unusual journal entries, informed by our understanding of the Company’s operations.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

 

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

 

Paul Winter BA FCA
For and on behalf of Taylor Associates, Statutory Auditor
Chartered Accountants
1st Floor Gallery Court
28 Arcadia Avenue
London
N3 2FG
22 May 2026
GONMISOL UK LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 4 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
7
98,918
114,937
Current assets
Stocks
95,843
166,957
Debtors
8
1,405,880
798,478
Cash at bank and in hand
766,564
589,268
2,268,287
1,554,703
Creditors: amounts falling due within one year
9
(2,301,415)
(1,635,213)
Net current liabilities
(33,128)
(80,510)
Total assets less current liabilities
65,790
34,427
Provisions for liabilities
(25,288)
(29,428)
Net assets
40,502
4,999
Capital and reserves
Called up share capital
10
1
1
Profit and loss reserves
40,501
4,998
Total equity
40,502
4,999

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 22 May 2026 and are signed on its behalf by:
Daniel Minguez
Anthony Weston
Director
Director
Company registration number 14496144 (England and Wales)
GONMISOL UK LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2025
31 December 2025
- 5 -
1
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

 

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

 

Impairment of assets

Stock is are reviewed for impairment at each reporting date to assess whether any current or future events and circumstances suggest that their recoverable amount may be less than the carrying value. Specifically with regards to stock, recoverability is also considered in light of the pricing on open, unfulfilled sales contracts as at the year-end and post year-end price movements.

2
Accounting policies
Company information

Gonmisol UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1st Floor Gallery Court, 28 Arcadia Avenue, London, N3 2FG.

2.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2
Accounting policies
(Continued)
- 6 -

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

 

 

The financial statements of the company are consolidated in the financial statements of Palmer Strategic Solutions, S.L. These consolidated financial statements are available from its registered office, Registro Mercantil de Madrid, Calle Principe de Vergara, 72, 28006, Madrid (Spain).

2.2
Going concern

The financial statements are prepared on a going concern basis.true

 

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. It is the director's assessment that the company continues to be a going concern and that no material uncertainties exist as a result of going concern.

 

Accordingly, the assets and liabilities have been valued on the basis that the company will continue in business.

2.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for sale of goods and services to external customers in the ordinary nature of the business. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates. Turnover is shown net of Value Added Tax. Revenue for sale of goods is recognised only when the risks and rewards have transferred to the customer according to shipping terms.

 

Turnover is recognised in relation to separately identifiable components of a single transaction when necessary to reflect the substance of the arrangement and in relation to two or more linked transactions when necessary to understand the commercial effect.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

2.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

IT equipment
5 years straight-line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
2
Accounting policies
(Continued)
- 7 -
2.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

2.6
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Cost is determined on a first in first out basis. Net realisable value is based on selling price less anticipated costs to completion and selling costs.estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

At each reporting date, the company assesses whether stocks are impaired or if an impairment loss is recognised in prior periods has reversed. Any excess of the carrying amount of stock over its estimated selling price less costs to complete and sell, is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

2.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

2.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
2
Accounting policies
(Continued)
- 8 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors and loans from fellow group companies are classified as debt, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, in which case the liability is measured at the present value of future payments discounted at a market rate of interest. Financial liabilities that are payable within one year are not amortised.. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

2.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
2
Accounting policies
(Continued)
- 9 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

2.10
Employee benefits

Employee benefits are accounted for in accordance with FRS 102 Section 28. The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

 

For defined contribution schemes the amount charged to profit or loss is the contributions payable in the year. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments.

2.11
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

For accounting periods beginning on or after 1 January 2026, the revised FRS 102 (September 2024 edition) will require most leases to be recognised on the balance sheet as right‑of‑use assets and lease liabilities, except for leases that qualify as short‑term or low‑value. This change does not affect the current reporting period.

2.12
Foreign exchange

Transactions in currencies other than the functional currency (foreign currency) are initially recorded at the exchange rate prevailing on the date of the transaction.

 

Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the reporting date. Non-monetary assets and liabilities denominated in foreign currencies are translated at the rate ruling at the date of the transaction, or, if the asset or liability is measured at fair value, the rate when that fair value was determined.

 

All translation differences are taken to profit or loss, except to the extent that they relate to gains or losses on non-monetary items recognised in other comprehensive income, when the related translation gain or loss is also recognised in other comprehensive income.

3
Turnover and interest income
2025
2024
£
£
Turnover analysed by class of business
Nutraceutical product sales
1,207,581
1,106,756
GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
3
Turnover and interest income
(Continued)
- 10 -
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
1,207,581
1,106,756
2025
2024
£
£
Interest Income
Bank Interest
-
1,877
4
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Executive Director(employee)
2
1
Executive Directors (not employed by the Company):
-
1
Employee
1
-
Total
3
2

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
1,556,338
55,000
Social security costs
45,994
4,542
Pension costs
48,197
16,417
1,650,529
75,959

 

5
Directors' remuneration
2025
2024
£
£
Remuneration paid to directors
1,561,460
71,417

Director remuneration for qualifying services during the year totalled £1,561,460 (2024: £71,417), comprising a basic salary of £ 296,025 (2024: £55,000), bonuses of £1,219,435 (2024: £0) and pension of £46,000 (2024: £16,417).

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
6
Taxation
2025
2024
£
£
Deferred tax
Movements in temporary differences
(4,140)
29,428
7
Tangible fixed assets
IT equipment
£
Cost
At 1 January 2025
141,392
Additions
14,168
At 31 December 2025
155,560
Depreciation and impairment
At 1 January 2025
26,455
Depreciation charged in the year
30,187
At 31 December 2025
56,642
Carrying amount
At 31 December 2025
98,918
At 31 December 2024
114,937
8
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
1,398,724
234,818
Amounts owed by group undertakings
-
0
558,382
Prepayments
7,156
5,278
1,405,880
798,478
9
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
20,965
142,447
Amounts owed to group undertakings
1,602,096
1,492,188
Taxation and social security
24,185
578
Other creditors
654,169
-
0
2,301,415
1,635,213
GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
9
Creditors: amounts falling due within one year
(Continued)
- 12 -

There are no formal loan agreements or repayment terms in place, and the intercompany loan balance is repayable on demand.

10
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
1 Ordinary share of £1 of 0p each
1
1
1
1
11
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Paul Winter
Statutory Auditor:
Taylor Associates
Date of audit report:
22 May 2026
12
Related party transactions

The company has taken advantage of the exemption permitted by FRS 102 Section 33 Related Party Disclosures, not to provide disclosures of transactions entered into with other wholly owned members of the group.

13
Fixed charge

On 30 July 2025, a fixed charge was registered over the Company’s bank accounts in favour of Ares Management Limited. This security was granted as part of the Group’s wider financing arrangements and therefore also serves as a cross-guarantee of Group borrowings. The charge does not give rise to additional liabilities in the Company’s balance sheet.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 13 -
14
Parent and Ultimate parent undertaking

The company's parent and ultimate parent is CEPI GmbH which is domiciled in Germany at the year end.

 

Until December 10th, 2025, the Company was a wholly owned subsidiary of SuanFarma, S.A., a company headquartered in Madrid, Spain. Effective December 10th 2025, Gonmisol UK Limited underwent a change in ownership.

 

As part of a transaction at the parent company level, 100% of the Company’s share capital was transferred from Suan Farma, S.A.U. to Productos Químicos Gonmisol, S.A.U., which became the Company’s direct parent.

 

Productos Químicos Gonmisol, S.A.U is wholly owned by Palmer Strategic Solutions, S.L., which in turn is wholly owned by Paterson Strategic Solutions, S.L. The change in ownership did not result in any change to the Company’s operations, assets or liabilities.

 

These financial statements are consolidated in Palmer Strategic Solutions, S.L.

The registered office address is Registro Mercantil de Madrid, Calle Principe de Vergara, 72, 28006, Madrid (Spain).

 

 

 

2025-12-312025-01-01falsefalsefalse22 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityCarlos CurtoDaniel MinguezAnthony Weston144961442025-01-012025-12-31144961442025-12-31144961442024-12-3114496144core:ComputerEquipment2025-12-3114496144core:ComputerEquipment2024-12-3114496144core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3114496144core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3114496144core:CurrentFinancialInstruments2025-12-3114496144core:CurrentFinancialInstruments2024-12-3114496144core:ShareCapital2025-12-3114496144core:ShareCapital2024-12-3114496144core:RetainedEarningsAccumulatedLosses2025-12-3114496144core:RetainedEarningsAccumulatedLosses2024-12-3114496144core:ShareCapitalOrdinaryShareClass12025-12-3114496144core:ShareCapitalOrdinaryShareClass12024-12-3114496144bus:Director22025-01-012025-12-3114496144bus:Director32025-01-012025-12-3114496144core:ComputerEquipment2025-01-012025-12-31144961442024-01-012024-12-3114496144core:ComputerEquipment2024-12-3114496144bus:OrdinaryShareClass12025-01-012025-12-3114496144bus:OrdinaryShareClass12025-12-3114496144bus:OrdinaryShareClass12024-12-3114496144bus:PrivateLimitedCompanyLtd2025-01-012025-12-3114496144bus:FRS1022025-01-012025-12-3114496144bus:Audited2025-01-012025-12-3114496144bus:Director12025-01-012025-12-3114496144bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3114496144bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP